Hell or Help is On the Way? –

November 8, 2018 – Compass Pathways has set itself up to be the first legal provider of psilocybin, having recently launched a massive clinical study across Europe and North America to test the drug as a treatment for depression. Last month, Compass’s psilocybin received “breakthrough therapy designation” from the US Food and Drug Administration (FDA) meaning the study will be hastened through the drug-development process. That puts Compass well ahead of other institutions working in this field—and a recently filed patent application could help the company stay ahead. Prior to founding Compass, George Goldsmith and Ekaterina Malievskaia, a married couple, did not have experience in psilocybin research or working in the pharmaceutical industry. They’ve made headway thanks to tens of millions in dollars from investors including Silicon Valley libertarian Peter Thiel and former Wall Street-executive-turned-cryptocurrency-investor Mike Novogratz, along with the expertise and guidance of many long-standing psilocybin researchers. (Neither Thiel nor Novogratz responded to requests for comment.)

Full Story @ QZ.com

SIGN UP TODAY!

Subscribe now and receive a FREE download of Russell Brand's interview with Dr. Gabor Maté (3/22/20) as they discuss: The Coronavirus, the infodemic, fear, acceptance, addiction, good books, and turning crisis into opportunity. Courtesy of Addiction Recovery eBulletin® with permission from Russell Brand and Dr. Gabor Maté.